Epkinly - Epcoritamab-bysp -弥漫性大b细胞淋巴瘤治疗的显著突破。

IF 0.9 Q4 ONCOLOGY
Rumaisa Riaz, Afsheen Khan, Tasmiyah Siddiqui
{"title":"Epkinly - Epcoritamab-bysp -弥漫性大b细胞淋巴瘤治疗的显著突破。","authors":"Rumaisa Riaz, Afsheen Khan, Tasmiyah Siddiqui","doi":"10.1177/20363613231193566","DOIUrl":null,"url":null,"abstract":"The most prevalent non-Hodgkin lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), affects 25,000 people annually and accounts for roughly 30% of cases of Non-Hodgkin Lymphoma. 1 Rituximab and chemotherapy are commonly used in the treatment of diffuse large B-cell lymphoma (DLBCL) to cure the patient; however, a signi fi cant portion of patients, up to 40%, are bound to experience relapsed or refractory disease. In such cases, salvage chemotherapy followed by autologous stem cell transplantation is the standard approach, but less than half of the patients achieve long-term disease control. 2 Those who face refractory disease or experience relapse after transplantation have limited treatment options and generally have poor overall survival rates. 2,3 To address this unmet medical need, the Food and Drug Administration (FDA) has recently given Epcoritamab-bysp (Epkinly, Genmab US, Inc.) accelerated approval for the treatment of relapsed or refractory DLBCL, including cases where DLBCL arises from indolent lymphoma or high-grade B-cell lymphoma after two or more lines of systemic therapy. This approval signi fi es an important advancement, providing a potential therapeutic option for patients who have exhausted standard treatments. 4","PeriodicalId":46078,"journal":{"name":"Rare Tumors","volume":"15 ","pages":"20363613231193566"},"PeriodicalIF":0.9000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/66/f3/10.1177_20363613231193566.PMC10392166.pdf","citationCount":"0","resultStr":"{\"title\":\"Epcoritamab-bysp (Epkinly) - A phenomenal breakthrough in the treatment of diffuse large B-cell lymphoma.\",\"authors\":\"Rumaisa Riaz, Afsheen Khan, Tasmiyah Siddiqui\",\"doi\":\"10.1177/20363613231193566\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The most prevalent non-Hodgkin lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), affects 25,000 people annually and accounts for roughly 30% of cases of Non-Hodgkin Lymphoma. 1 Rituximab and chemotherapy are commonly used in the treatment of diffuse large B-cell lymphoma (DLBCL) to cure the patient; however, a signi fi cant portion of patients, up to 40%, are bound to experience relapsed or refractory disease. In such cases, salvage chemotherapy followed by autologous stem cell transplantation is the standard approach, but less than half of the patients achieve long-term disease control. 2 Those who face refractory disease or experience relapse after transplantation have limited treatment options and generally have poor overall survival rates. 2,3 To address this unmet medical need, the Food and Drug Administration (FDA) has recently given Epcoritamab-bysp (Epkinly, Genmab US, Inc.) accelerated approval for the treatment of relapsed or refractory DLBCL, including cases where DLBCL arises from indolent lymphoma or high-grade B-cell lymphoma after two or more lines of systemic therapy. This approval signi fi es an important advancement, providing a potential therapeutic option for patients who have exhausted standard treatments. 4\",\"PeriodicalId\":46078,\"journal\":{\"name\":\"Rare Tumors\",\"volume\":\"15 \",\"pages\":\"20363613231193566\"},\"PeriodicalIF\":0.9000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/66/f3/10.1177_20363613231193566.PMC10392166.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Rare Tumors\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/20363613231193566\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Rare Tumors","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/20363613231193566","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

本文章由计算机程序翻译,如有差异,请以英文原文为准。
Epcoritamab-bysp (Epkinly) - A phenomenal breakthrough in the treatment of diffuse large B-cell lymphoma.
The most prevalent non-Hodgkin lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), affects 25,000 people annually and accounts for roughly 30% of cases of Non-Hodgkin Lymphoma. 1 Rituximab and chemotherapy are commonly used in the treatment of diffuse large B-cell lymphoma (DLBCL) to cure the patient; however, a signi fi cant portion of patients, up to 40%, are bound to experience relapsed or refractory disease. In such cases, salvage chemotherapy followed by autologous stem cell transplantation is the standard approach, but less than half of the patients achieve long-term disease control. 2 Those who face refractory disease or experience relapse after transplantation have limited treatment options and generally have poor overall survival rates. 2,3 To address this unmet medical need, the Food and Drug Administration (FDA) has recently given Epcoritamab-bysp (Epkinly, Genmab US, Inc.) accelerated approval for the treatment of relapsed or refractory DLBCL, including cases where DLBCL arises from indolent lymphoma or high-grade B-cell lymphoma after two or more lines of systemic therapy. This approval signi fi es an important advancement, providing a potential therapeutic option for patients who have exhausted standard treatments. 4
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Rare Tumors
Rare Tumors ONCOLOGY-
CiteScore
1.50
自引率
0.00%
发文量
15
审稿时长
15 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信